When a new biotech’s drug pipeline is more of a ‘hypeline’ - STAT

When a new biotech’s drug pipeline is more of a ‘hypeline’ - STAT

STAT Plus: When a new biotech’s drug pipeline is more of a ‘hypeline’

By KATE SHERIDAN

ADOBE

It’s a tongue-in-cheek moniker for the overly braggadocious renderings of the drug candidates and therapies a new company hopes to bring to market.

READ MORE